Andrew D. Goldberg - Jun 22, 2023 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Jun 22, 2023
Transactions value $
$0
Form type
4
Date filed
6/26/2023, 05:56 PM
Previous filing
Jun 21, 2023
Next filing
Dec 19, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +5K $0.00 5K Jun 22, 2023 Common Stock 5K $17.99 Direct F1
transaction TARS Restricted Stock Units Award $0 +3.35K $0.00 3.35K Jun 22, 2023 Common Stock 3.35K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.